Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Review uri icon

Overview

abstract

  • Polycythemia vera (PV) is a myeloproliferative disease which if untreated leads to thrombohemorrhagic complications and eventually to progressive myelofibrosis of the marrow, anemia, and splenomegaly. Two new drugs are now available, interferon and imatinib mesylate, which may alter the course of this disease. Used as single agents, each produces lasting remissions in about 75% of the cases.

publication date

  • May 1, 2005

Research

keywords

  • Immunologic Factors
  • Interferon Type I
  • Piperazines
  • Polycythemia Vera
  • Protein Kinase Inhibitors
  • Pyrimidines

Identity

Scopus Document Identifier

  • 23844481514

PubMed ID

  • 15865878

Additional Document Info

volume

  • 4

issue

  • 3